Skip to main content

Table 4 Associations of categorical mammographic density with breast cancer overall and by morphological subtypes

From: Mammographic density and risk of breast cancer by age and tumor characteristics

 

Number of cases

Number of controls

Odds ratio (95% CI)a

P heterogeneity b

Overall breast cancer

    

   0 to 10%

430

1,485

0.65 (0.56, 0.74)

 

   11 to 25% (reference)

872

2,248

1.00 (reference)

 

   26 to 50%

1,379

2,386

1.65 (1.48, 1.84)

 

   51%+

733

1,080

2.15 (1.88, 2.46)

 

Invasiveness

    

Invasive

   

0.46

   0 to 10%

372

1,485

0.66 (0.57, 0.76)

 

   11 to 25% (reference)

730

2,248

1.00 (reference)

 

   26 to 50%

1,129

2,386

1.65 (1.47, 1.86)

 

   51%+

605

1,080

2.21 (1.92, 2.55)

 

In situ

    

   0 to 10%

52

1,485

0.54 (0.38, 0.75)

 

   11 to 25% (reference)

139

2,248

1.00 (reference)

 

   26 to 50%

240

2,386

1.60 (1.28, 2.00)

 

   51%+

124

1,080

1.87 (1.42, 2.48)

 

Histology c

   

0.04

Ductal

    

   0 to 10%

281

1,485

0.66 (0.56, 0.78)

 

   11 to 25% (reference)

556

2,248

1.00 (reference)

 

   26 to 50%

884

2,386

1.66 (1.46, 1.88)

 

   51%+

466

1,080

2.14 (1.83, 2.51)

 

Lobular

    

   0 to 10%

44

1,485

0.54 (0.37, 0.78)

 

   11 to 25% (reference)

100

2,248

1.00 (reference)

 

   26 to 50%

119

2,386

1.36 (1.03, 1.80)

 

   51%+

84

1,080

2.69 (1.93, 3.74)

 

Histologic grade

   

0.89

Well differentiated

    

   0 to 10%

107

1,485

0.61 (0.47, 0.77)

 

   11 to 25% (reference)

228

2,248

1.00 (reference)

 

   26 to 50%

295

2,386

1.41 (1.17, 1.70)

 

   51%+

169

1,080

2.12 (1.68, 2.67)

 

Moderately differentiated

    

   0 to 10%

146

1,485

0.69 (0.56, 0.86)

 

   11 to 25% (reference)

270

2,248

1.00 (reference)

 

   26 to 50%

430

2,386

1.70 (1.44, 2.02)

 

   51%+

232

1,080

2.31 (1.87, 2.84)

 

Poorly differentiated

    

   0 to 10%

75

1,485

0.65 (0.48, 0.87)

 

   11 to 25% (reference)

148

2,248

1.00 (reference)

 

   26 to 50%

273

2,386

1.90 (1.53, 2.35)

 

   51%+

143

1,080

2.34 (1.80, 3.04)

 

Tumor size

   

<0.001

<1.1 cm

    

   0 to 10%

179

1,485

0.93 (0.76, 1.14)

 

   11 to 25% (reference)

265

2,248

1.00 (reference)

 

   26 to 50%

353

2,386

1.37 (1.15, 1.63)

 

   51%+

172

1,080

1.61 (1.29, 2.01)

 

1.1 to 2.0 cm

    

   0 to 10%

121

1,485

0.54 (0.43, 0.67)

 

   11 to 25% (reference)

294

2,248

1.00 (reference)

 

   26 to 50%

453

2,386

1.64 (1.39, 1.93)

 

   51%+

253

1,080

2.27 (1.86, 2.77)

 

2.1+ cm

    

   0 to 10%

56

1,485

0.42 (0.30, 0.57)

 

   11 to 25% (reference)

154

2,248

1.00 (reference)

 

   26 to 50%

280

2,386

2.07 (1.67, 2.57)

 

   51%+

159

1,080

3.12 (2.41, 4.04)

 

Involvement of lymph nodes

   

0.01

Negative

    

   0 to 10%

257

1,485

0.67 (0.57, 0.79)

 

   11 to 25% (reference)

508

2,248

1.00 (reference)

 

   26 to 50%

744

2,386

1.54 (1.35, 1.76)

 

   51%+

406

1,080

2.07 (1.76, 2.44)

 

Positive

    

   0 to 10%

65

1,485

0.52 (0.38, 0.70)

 

   11 to 25% (reference)

157

2,248

1.00 (reference)

 

   26 to 50%

298

2,386

1.99 (1.61, 2.45)

 

   51%+

164

1,080

2.67 (2.07, 3.44)

 

Estrogen receptor status

   

0.66

Negative

    

   0 to 10%

48

1,485

0.61 (0.43, 0.88)

 

   11 to 25% (reference)

106

2,248

1.00 (reference)

 

   26 to 50%

192

2,386

1.79 (1.39, 2.30)

 

   51%+

102

1,080

2.18 (1.61, 2.96)

 

Positive

    

   0 to 10%

305

1,485

0.65 (0.56, 0.77)

 

   11 to 25% (reference)

596

2,248

1.00 (reference)

 

   26 to 50%

880

2,386

1.60 (1.41, 1.82)

 

   51%+

479

1,080

2.22 (1.9, 2.60)

 

Progesterone receptor status

  

0.10

Negative

    

   0 to 10%

90

1,485

0.65 (0.50, 0.85)

 

   11 to 25% (reference)

187

2,248

1.00 (reference)

 

   26 to 50%

288

2,386

1.59 (1.30, 1.94)

 

   51%+

151

1,080

1.99 (1.56, 2.55)

 

Positive

    

   0 to 10%

265

1,485

0.66 (0.56, 0.78)

 

   11 to 25% (reference)

512

2,248

1.00 (reference)

 

   26 to 50%

782

2,386

1.65 (1.45, 1.89)

 

   51%+

424

1,080

2.28 (1.93, 2.68)

 

HER2 status

   

0.69

Negative

    

   0 to 10%

189

1,485

0.66 (0.54, 0.80)

 

   11 to 25% (reference)

367

2,248

1.00 (reference)

 

   26 to 50%

560

2,386

1.63 (1.40, 1.90)

 

   51%+

298

1,080

2.06 (1.70, 2.49)

 

Positive

    

   0 to 10%

31

1,485

0.62 (0.40, 0.97)

 

   11 to 25% (reference)

62

2,248

1.00 (reference)

 

   26 to 50%

116

2,386

1.94 (1.40, 2.69)

 

   51%+

60

1,080

2.33 (1.57, 3.45)

 
  1. CI, confidence interval; HER2, human epidermal growth factor receptor 2. aAdjusted for age, body mass index, and study.
  2. bTest of heterogeneity in associations by subtype (Ptrend for categories with natural ordering; that is, tumor size and histologic grade).
  3. cMixed and other histology categories are excluded.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us